Singapore, June 17 -- StemSight, a Finnish biotechnology startup developing off-the-shelf regenerative cell therapies for curing blindness, has been granted a patent in Singapore, and received a notice of patent allowance in Canada and Japan, covering the company's proprietary technology.

The patents strengthen StemSight's position in the rapidly emerging field of off-the-shelf regenerative medicine and come as the company prepares for its upcoming Series A financing round.

The granted patent family, titled Method for Obtaining or Maintaining ABCG2-Positive Corneal Limbal Cells, protects StemSight's unique approach in developing STE-101, the company's novel product for replacing lost limbal stem cells used in the treatment of limbal ste...